Dimerix (ASX:DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets.
Dimerix is currently developing its proprietary product DMX-200 for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients as well as in two different kidney disease, Diabetic Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS).
Dimerix's lead clinical drug candidate, DMX-200, was selected for inclusion in the global REMAP CAP study for patients with Acute Respiratory Distress Syndrome associated with COVID-19. DMX-200 therapy is aimed at reducing damage from inflammatory immune cells by blocking their signalling and limiting subsequent movement. Patients hospitalised with COVID-19 commonly have acute lung dysfunction due to the immune response to the virus. Global experts see DMX-200 as a compelling treatment option to limit inflammation in the lungs during infection of the SARS-CoV2 virus.
REMAP-CAP is a global WHO-endorsed study designed to rapidly generate evidence for treatments in patients with respiratory distress associated with COVID-19.
BTB Round: Third
Visit Dimerix for more information.
LinkedIn: Dimerix Limited
Contact: Dr Nina Webster